Add listing
    0
    Add listing

    Vaximm AG Verified listing

    • Swiss Biotech Association
      Not a member

    VAXIMM is developing oral T-cell immunotherapies for cancer patients. VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria carrying a eukaryotic expression plasmid which enables targeting of tumor-related antigens including personalized neoantigens

    Location
    Canton
    Facts & figures
    • Type of organization
      Private company
    • Year of foundation
      2008
    • Number of employees in Switzerland
      1-9
    Key business

    You may also be interested in